Spectrum Pharmaceuticals

Spectrum Pharmaceuticals is a commercial-stage biotechnology company with fully integrated commercial and drug development operations, and a focus in oncology and hematology. Our primary strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. In addition to an efficient in-house clinical development organization with regulatory and data management capabilities, Spectrum has established a commercial infrastructure for its marketed products. Currently, we have six oncology/hematology products on the market that target different types of non-Hodgkin's lymphoma, advanced metastatic colorectal cancer, a type of acute lymphoblastic leukemia (ALL) and multiple myeloma. Spectrum also has two drugs in late stage development: SPI-2012, being developed for chemotherapy-induced neutropenia in patients with breast cancer. Apaziquone being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. Our passion to identify, develop and deliver important options for patients suffering from cancer is behind every action we take. At Spectrum, we are committed to excellence and strive to make a difference in the lives of patients every day.
Type
Public
HQ
Henderson, US
Founded
2002
Size (employees)
212 (est)
Website
sppirx.com
Spectrum Pharmaceuticals was founded in 2002 and is headquartered in Henderson, US

Spectrum Pharmaceuticals Office Locations

Spectrum Pharmaceuticals has an office in Henderson
Henderson, US (HQ)
240 11500 S Eastern Ave

Spectrum Pharmaceuticals Metrics

Spectrum Pharmaceuticals Financial Metrics

Revenue (2016)

$146.4 m

Revenue growth (2015-16), %

7%

Gross profit

$118.5 m

Gross profit margin (2016), %

81%

Net income (2016)

($68.5 m)

Market capitalization (10-Mar-2017)

$499.4 m

Closing share price (10-Mar-2017)

$6.1

Cash (31-Dec-2016)

$158.2 m
Spectrum Pharmaceuticals's current market capitalization is $499.4 m.
Spectrum Pharmaceuticals's revenue was reported to be $146.4 m in 2016
FY, 2013FY, 2014FY, 2015Y, 2016

Revenue

$143.5 m$186.5 m$136.9 m$146.4 m

Revenue growth, %

30%(27%)7%

Cost of goods sold

$28.6 m$27 m$27.7 m$28 m

Gross profit

$114.9 m$159.5 m$109.2 m$118.5 m

Gross profit Margin, %

80%86%80%81%

Operating expense total

$194.6 m$218.4 m$203.3 m$208.1 m

EBIT

($38.8 m)($31.6 m)($40.7 m)($61.6 m)

EBIT margin, %

(27%)(17%)(30%)(42%)

Interest expense

($2.2 m)($8.6 m)($9.1 m)($9.4 m)

Interest income

($2.2 m)($8.6 m)($9.1 m)($9.4 m)

Pre tax profit

($36.6 m)($43.5 m)($50.4 m)($70.8 m)

Income tax expense

($25.5 m)($2.2 m)($406 k)

Net Income

($62.1 m)($45.7 m)($50.8 m)($68.5 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$156.3 m$129.9 m$139.7 m$158.2 m

Accounts Receivable

$7.5 m$5.5 m$12.6 m$5.8 m

Inventories

$13.5 m$9.2 m$4.2 m$8.7 m

Current Assets

$235.2 m$222.5 m$191.3 m$216.7 m

PP&E

$1.5 m$1.4 m$918 k$449 k

Goodwill

$18.5 m$18.2 m$18 m$17.9 m

Total Assets

$499.2 m$490 m$421.2 m$428.8 m

Accounts Payable

Current Liabilities

$90 m$109.4 m$76.3 m$65.5 m

Preferred Stock

$123 k

Additional Paid-in Capital

$518.1 m$538.6 m$552.1 m$640.2 m

Retained Earnings

($237.6 m)($283.3 m)($334.1 m)($402.6 m)

Total Equity

$281.6 m$254.6 m$212.9 m$236 m

Financial Leverage

1.8 x1.9 x2 x1.8 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($62.1 m)($45.7 m)($50.8 m)($68.5 m)

Depreciation and Amortization

$22.1 m$25.4 m$31.9 m$26.5 m

Accounts Receivable

$42.6 m($22 m)$40.2 m($9.5 m)

Inventories

$1.6 m$4.3 m$1.9 m($5.8 m)

Accounts Payable

Cash From Operating Activities

($2.1 m)($3.6 m)$6.7 m($40.5 m)

Purchases of PP&E

($161 k)($934 k)($223 k)($78 k)

Cash From Investing Activities

($14.3 m)($21.8 m)$2.8 m($679 k)

Cash From Financing Activities

$35.3 m$812 k$1.5 m$59.6 m

Interest Paid

$1.2 m$3.2 m$3.3 m$3.3 m

Income Taxes Paid

$329 k$335 k$11 k

Spectrum Pharmaceuticals Market Value History

Spectrum Pharmaceuticals Company Life

You may also be interested in